- Home
- URGN vs RFAI Comparison
URGN vs RFAI Comparison
Compare URGN & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- RFAI
- Stock Information
- Founded
- URGN 2004
- RFAI 2024
- Country
- URGN United States
- RFAI Singapore
- Employees
- URGN N/A
- RFAI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- RFAI
- Sector
- URGN Health Care
- RFAI
- Exchange
- URGN Nasdaq
- RFAI NYSE
- Market Cap
- URGN 181.2M
- RFAI 157.3M
- IPO Year
- URGN 2017
- RFAI 2024
- Fundamental
- Price
- URGN $14.82
- RFAI $10.53
- Analyst Decision
- URGN Strong Buy
- RFAI
- Analyst Count
- URGN 9
- RFAI 0
- Target Price
- URGN $26.81
- RFAI N/A
- AVG Volume (30 Days)
- URGN 5.9M
- RFAI 4.5K
- Earning Date
- URGN 08-12-2025
- RFAI 01-01-0001
- Dividend Yield
- URGN N/A
- RFAI N/A
- EPS Growth
- URGN N/A
- RFAI N/A
- EPS
- URGN N/A
- RFAI 0.32
- Revenue
- URGN $91,871,000.00
- RFAI N/A
- Revenue This Year
- URGN $36.65
- RFAI N/A
- Revenue Next Year
- URGN $88.35
- RFAI N/A
- P/E Ratio
- URGN N/A
- RFAI $32.95
- Revenue Growth
- URGN 8.98
- RFAI N/A
- 52 Week Low
- URGN $3.42
- RFAI $10.00
- 52 Week High
- URGN $18.15
- RFAI $10.60
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- RFAI N/A
- Support Level
- URGN $6.92
- RFAI N/A
- Resistance Level
- URGN $15.22
- RFAI N/A
- Average True Range (ATR)
- URGN 1.57
- RFAI 0.00
- MACD
- URGN 1.17
- RFAI 0.00
- Stochastic Oscillator
- URGN 96.49
- RFAI 0.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.